Chimerism and tolerance after bone marrow transplantation provide excellent conditions for adoptive immunotherapy with T cells of the marrow donor. We studied adoptive immunotherapy in dog leukocyte antigen-identical canine littermate chimeras. Mixed chimeras were produced by conditioning treatment with total body irradiation of a dose of 10 Gy, a uniformly lethal dose in dogs, and infusion of between 1 x 10(8) and 2 x 10(8)/kg mononuclear marrow cells treated with absorbed antithymocyte globulin for inactivation of T cells. Donors were of opposite sex. Persistent mixed chimerism was induced in six of nine dogs, chimerism was complete in one dog, and only transient in two dogs. Tolerance to donor skin grafts was demonstrated in eight dogs, including a dog without cytogenetic evidence of chimerism. Lymphocytes of the marrow donor (between 3.2 x 10(8)/kg and 4.1 x 10(8)/kg) were transfused at various times after transplantation. Nontransfused dogs survived without graft-versus-host disease (GVHD), whereas dogs transfused on days 1 and 2 and dogs transfused on days 21 and 22 developed GVHD and died. In contrast, dogs transfused on days 61 and 62 or later survived without GVHD. Chimerism converted from mixed to complete in six of six transfused dogs and in one of eight nontransfused dogs (P<0.005). Donor lymphocyte transfusions 2 years and 4.5 years after transplantation induced split chimerism with lymphoid cells of donor origin and myeloid cells of host origin in one dog and complete chimerism in the other dog. Before lymphocyte collection, donors were immunized against tetanus toxin. Seven days after lymphocyte transfusion, recipients were given booster injections of tetanus toxoid and primary immunization against diphtheria toxin. In transfused animals, antibody titers against tetanus were demonstrated already before the booster injection. Transfused animals developed higher titers of antibody against tetanus and diphtheria toxin than nontransfused animals. Donor lymphocytes converted mixed chimerism into complete chimerism without producing GVHD, when the transfusion was delayed for 2 months or later after transplantation. Transfusion of donor lymphocytes transferred immune reactivity against tetanus toxin and improved reactivity against diphtheria toxin as a new antigen.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/00007890-199702150-00017 | DOI Listing |
Cancer Rep (Hoboken)
March 2025
Department of Oncology, KU Leuven, Leuven, Belgium.
Background: CD19-directed chimeric antigen receptor T-cell therapy tisagenlecleucel has shown promising results in the treatment of pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, around 50% of patients relapse after tisagenlecleucel. Following multiple relapses, limited treatment options are left, and the prognosis is dismal.
View Article and Find Full Text PDFRecenti Prog Med
March 2025
Uoc Ctmo Grande Ospedale Metropolitano (Gom) "Bianchi-Melacrino-Morelli", Reggio Calabria.
Introduction: Mantle cell lymphoma (MCL) is one of the rarest forms of non-Hodgkin's lymphoma that mainly affects adults around 65 years of age or older, and is diagnosed when the disease has already reached a fairly advanced stage. Partly for this reason, but mainly because of the very characteristics of this rare form of lymphoma, the prognosis is often poor. In most cases, the disease recurs after a period of remission achieved with I-line.
View Article and Find Full Text PDFRecenti Prog Med
March 2025
SC Ematologia, Aou Città della Salute e della Scienza di Torino.
Introduction: Relapsed or refractory (R/R) mantle cell lymphoma (MCL) represent a setting at unfavourable prognosis. Chimeric antigen receptor T-cells (CAR-T) are recently introduced in clinical practice as a new therapeutic option for this setting.
Clinical Case: 61-year-old man with MCL pleomorphic variant, TP53 mutated with high risk MIPI-c early relapsed after frontline immunochemotherapy and ibrutinib.
Recenti Prog Med
March 2025
Unità operativa di ematologia, Asst Spedali Civili di Brescia.
Mantle cell lymphoma is a rare and aggressive hematologic malignancy characterized by frequent relapses and poor prognosis. Recently, the approval of CAR-T cell therapy has transformed the treatment landscape for relapsed/refractory patients. We report the case of a 52-year-old patient with mantle cell lymphoma who experienced multiple disease relapses.
View Article and Find Full Text PDFJ Immunother Cancer
March 2025
Department of Oncology, Ludwig Cancer Research Lausanne Branch, University of Lausanne, Lausanne, Switzerland
Background: The glycosylphosphatidylinositol-anchored cell surface protein mesothelin (MSLN) shows elevated expression in many malignancies and is an established clinical-stage target for antibody-directed therapeutic strategies. Of these, the harnessing of autologous patient T cells via engineered anti-MSLN chimeric antigen receptors (CAR-T) is an approach garnering considerable interest. Although generally shown to target tumor MSLN safely, CAR-T trials have failed to deliver the impressive curative or response metrics achieved for hematological malignancies using the same technology.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!